Business Context and Reporting Period
This Form 8-K, filed on January 29, 1997, by E. I. du Pont de Nemours and Company (DuPont), reports record fourth-quarter and full-year 1996 earnings. The filing includes an earnings press release and consolidated financial statements for the three months and full year ended December 31, 1996, compared to the same periods in 1995. Effective in the fourth quarter of 1996, the company reorganized its reporting structure, splitting the former "Diversified Businesses" segment into a new "Life Sciences" segment (agricultural products and pharmaceuticals) and a revised "Diversified Businesses" segment.
Key Financial Metrics
| Metric | Q4 1996 | Q4 1995 | Full Year 1996 | Full Year 1995 |
|---|---|---|---|---|
| Sales | $11.4 billion | $10.4 billion | $43.8 billion | $42.2 billion |
| Net Income | $858 million | $627 million | $3.6 billion | $3.3 billion |
| Earnings Per Share (EPS) | $1.52 | $1.13 | $6.47 | $5.61 |
| Dividends Per Share | $0.57 | $0.52 | $2.23 | $2.03 |
| Petroleum Segment Earnings | $213 million | $79 million | $901 million | $664 million (adj.) |
| Chemicals Segment Earnings | $138 million | $149 million | $584 million (adj.) | $641 million (adj.) |
Liquidity and Debt: Management stated the company has regained financial flexibility by essentially completing the repayment of $8 billion in debt incurred in 1995 to redeem shares from Seagram. Additionally, the company repurchased 156 million warrants issued to Seagram for $500 million.
Material Changes Versus Prior Period
- Earnings Growth: Full-year 1996 earnings per share increased 14% to $6.65 (excluding nonrecurring items) compared to $5.81 in 1995. Q4 1996 EPS was up 19% on an adjusted basis.
- Petroleum Performance: Upstream petroleum earnings surged 46% to a record $706 million, driven by a 21% increase in crude oil prices (averaging $20.11/barrel) and a 32% increase in U.S. natural gas prices.
- Volume vs. Price: Worldwide sales volume increased 10% in Q4, but average selling prices were 4% lower than the prior year. For the full year, total sales rose 4% despite a 1% decline in average selling prices in the Chemicals and Specialties segment.
- Segment Shifts: The Life Sciences segment earnings grew 21% to $789 million, largely due to favorable income allocations from the DuPont Merck Pharmaceutical joint venture. Conversely, Diversified Businesses earnings fell 41% due to the divestiture of medical products.
Guidance, Outlook, and Risks
Outlook: CEO John A. Krol expects 1997 to be another strong year, citing momentum from double-digit volume growth in Chemicals and Specialties and strong upstream market conditions. The company noted major refinery upgrades were completed in 1996.
Risks and Contingencies:
- Nonrecurring Items: The filing details various charges and benefits, including a $110 charge for the "Benlate" fungicide recall, $63 for a write-down of a European natural gas marketing joint venture investment, and $45 for asset write-downs.
- Market Volatility: Results are heavily influenced by crude oil and natural gas prices, which fluctuated significantly (e.g., worldwide gas prices increased 619% year-over-year).
- Restructuring: Ongoing costs related to employee separations and facility shutdowns impacted downstream earnings in the second half of the year.
Investor Verification Checklist
- Verify the sustainability of upstream petroleum earnings given the high volatility in crude oil and natural gas prices.
- Confirm the impact of the "Benlate" fungicide recall litigation on future cash flows and reserves.
- Assess the long-term profitability of the new "Life Sciences" segment structure and the stability of income allocations from the DuPont Merck joint venture.
- Review the status of the $8 billion debt repayment and the $500 million warrant repurchase to confirm the stated improvement in financial flexibility.
- Monitor the performance of the Chemicals segment, which saw a 9% decline in earnings despite volume growth, due to lower prices and investment write-offs.